F6Publishing

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Articles Published Processes

Keyword: Erlotinib

Page 1 of 1 ( 11 items )
<<
1
>>

1	Clinical efficacy and safety of erlotinib combined with chemotherapy in the treatment of advanced pancreatic cancer: A meta-analysis 3/22/2024 11:13:53 AM \| Browse: 268 \| Download: 918
2	Erlotinib combination with a mitochondria-targeted ubiquinone effectively suppresses pancreatic cancer cell survival 2/21/2024 9:11:33 AM \| Browse: 386 \| Download: 1621
3	Therapy-related myeloid leukemia during erlotinib treatment in a non-small cell lung cancer patient: A case report 8/24/2021 2:07:00 AM \| Browse: 676 \| Download: 2093
4	Sustained complete response to erlotinib in squamous cell carcinoma of the head and neck: A case report 3/6/2019 8:51:28 AM \| Browse: 1052 \| Download: 1965
5	Chemotherapy and target therapy for hepatocellular carcinoma: New advances and challenges 4/19/2015 5:46:00 PM \| Browse: 1469 \| Download: 2199
6	Erlotinib usage after prior treatment with gefitinib in advanced non-small cell lung cancer: A clinical perspective and review of published literature 12/11/2014 2:06:00 PM \| Browse: 1164 \| Download: 1686
7	First-line erlotinib and fixed dose-rate gemcitabine for advanced pancreatic cancer 9/15/2014 8:54:00 PM \| Browse: 1436 \| Download: 1462
8	FDG-PET for predicting efficacy of EGFR-tyrosine kinase inhibitors in lung cancer 9/15/2014 4:56:00 PM \| Browse: 1310 \| Download: 1595
9	Targeting receptor tyrosine kinases in gastric cancer 8/28/2014 5:50:00 PM \| Browse: 1406 \| Download: 1700
10	Distinct antifibrogenic effects of erlotinib, sunitinib and sorafenib on rat pancreatic stellate cells 8/26/2014 1:51:00 PM \| Browse: 1186 \| Download: 1330
11	Translational research in pancreatic ductal adenocarcinoma: current evidence and future concepts 8/20/2014 6:38:00 PM \| Browse: 1615 \| Download: 1631

Page 1 of 1 ( 11 items )
<<
1
>>

Write to the Help Desk

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.